Fortem Neurosciences Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

Fortem Neurosciences General Information

Description

Developer of novel small-molecule drugs intended to eliminate Alzheimer's, Dementia, and other brain diseases. The company focuses on the development of molecular drugs that function as regulators of gene expression and have shown significant activity in animal models of cognitive decline, allowing scientists and medical professionals to find an exact cure for long-lasting diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 12100 Wilshire Boulevard
  • Suite 800
  • Los Angeles, CA 90025
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 12100 Wilshire Boulevard
  • Suite 800
  • Los Angeles, CA 90025
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fortem Neurosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 01-Apr-2024 Completed Startup
1. Early Stage VC (Series A) 12-May-2016 Completed Startup
To view Fortem Neurosciences’s complete valuation and funding history, request access »

Fortem Neurosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Fortem Neurosciences’s complete cap table history, request access »

Fortem Neurosciences Patents

Fortem Neurosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023408901-A1 Methods and compositions for the treatment of parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, and learning disorders Pending 20-Dec-2022
EP-4637745-A1 Methods and compositions for the treatment of parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, and learning disorders Pending 20-Dec-2022
US-20260207585-A1 Methods and compositions for the treatment of parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, and learning disorders Pending 20-Dec-2022
WO-2024137659-A1 Methods and compositions for the treatment of parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, and learning disorders Inactive 20-Dec-2022
AU-2021320639-A1 Compositions and methods for treating alzheimer's disease Pending 03-Aug-2020 A61K31/548
To view Fortem Neurosciences’s complete patent history, request access »

Fortem Neurosciences FAQs

  • When was Fortem Neurosciences founded?

    Fortem Neurosciences was founded in 2016.

  • Where is Fortem Neurosciences headquartered?

    Fortem Neurosciences is headquartered in Los Angeles, CA.

  • What industry is Fortem Neurosciences in?

    Fortem Neurosciences’s primary industry is Drug Discovery.

  • Is Fortem Neurosciences a private or public company?

    Fortem Neurosciences is a Private company.

  • What is Fortem Neurosciences’s current revenue?

    The current revenue for Fortem Neurosciences is .

  • How much funding has Fortem Neurosciences raised over time?

    Fortem Neurosciences has raised $2M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process